Selexipag

Selexipag, sold under the brand name Uptravi, is a medication developed by Actelion for the treatment of pulmonary arterial hypertension (PAH).[1] Selexipag and its active metabolite, ACT-333679 (or MRE-269, the free carboxylic acid), are agonists of the prostacyclin receptor, which leads to vasodilation in the pulmonary circulation.[2] It is taken by mouth or administered intravenously.[1][3] Contents 1 Contraindications 2 Adv... [wikipedia]